Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyramax in Mild to Moderate COVID-19 Pilot
NCT05633420Phase 2Completed
- Sponsor
- Shinpoong Pharma
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyronaridine in coronavirus disease 2019 (COVID-19), sponsored by Shinpoong Pharma. Primary endpoint: Time to negative conversion of COVID-19 infectious viable virus at Day 29. Started Jul 2022; status: completed.
02
Drugs
pyronaridine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05633420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633420.